YD Bio (YDES) Other Non-Current Assets (2025)
YD Bio's (YDES) quarterly Other Non-Current Assets came in at $1431.7 billion in Q4 2025.
YD Bio (YDES) Other Non-Current Assets (2025) Analysis & Trends
YD Bio (YDES) has 1 years of Other Non-Current Assets data on file, last reported at $1431.7 billion in Q4 2025.
- On a quarterly basis, Other Non-Current Assets changed N/A year-over-year to $1431.7 billion in Q4 2025; TTM through Dec 2025 was $1431.7 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $1431.7 billion, changed N/A from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $1431.7 billion.
- Over the last five years, Other Non-Current Assets for YDES reached as high as $1431.7 billion in Q4 2025 and fell as low as $1431.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 60,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 104.24 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 14.48 Mn |
| 10 | YD Bio | 157.46 Mn | 151.45 Mn | - | 1,431.66 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1,431.66 Bn |